BMS’s Orencia (abatacept) Receives the US FDA’s Approval for the Prevention of Acute Graft Versus Host Disease
Shots:
- The approval is based on the P-II (GVHD-1) trial to evaluate Orencia + CNI and MTX vs PBO + CNI and MTX in adults and pediatric patients aged ≥2yrs. for the prevention of aGvHD in patients who undergoes HSCT from a matched or 1 allele-mismatched URD
- In the GVHD-1 trial, abatacept showed an improved severe (grade III-IV) aGvHD-free survival in 7/8 mismatched unrelated donor transplant and associated mortality. In the 8/8 HLA-matched cohort, grade III-IV & grade II-IV aGvHD-free survival was (87% vs 75%) & (50% vs 32%) respectively
- Orencia is a selective costimulation modulator that disrupts the continuous cycle of T-cell activation & the approval marks the 4th indication for Orencia
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com